ACTRN12617001118392招募中2 期
Safety and efficacy of oral vinorelbine in treatment of ectopic pregnancies
orth Shore Hospital0 个研究点目标入组 20 人开始时间: 2017年7月31日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 50 Years（—）
- 性别
- Female
入选标准
- •Aged 18-50 years old
- •English speaking
- •Able to provide informed consent to participate
- •A diagnosis of a tubal ectopic pregnancy on transvaginal ultrasound
- •A stable ectopic pregnancy (no evidence of bleeding or rupture)
- •A pre-treatment serum Human Chorionic Gonadotrophin (hCG) level of 1,000 – 3,000 IU/L
- •Adnexal mass less than or equal to 3.0 cm, with no fetal cardiac activity
排除标准
- •Unable to provide informed consent to participate
- •A multiple pregnancy
- •Contraindication(s) to vinorelbine or to medical management of ectopic pregnancy
- •Immunodeficiency disorder(s)
- •A current malignancy
- •Received chemotherapy or radiation therapy in the previous five years
- •Concomitant disease which could significantly impair gastric absorption (Inflammatory bowel disease, coeliac, etc.)
- •History of surgical resection of the stomach/small bowel
- •Breastfeeding
- •Hepatic impairment, renal impairment, or haematological toxicity
研究者
相似试验
进行中（未招募）
1 期
Phase II study evaluating oral vinorelbine as a single agent in patients with hormone receptor breast cancer with bone metastases previously treated by a hormone therapyBreast cancer with bone metastases previously treated by a hormone therapy.MedDRA version: 12.1Level: LLTClassification code 10027475Term: <Manually entered code. Term in E.1.1>EUCTR2009-014497-18-FRPIERRE FABRE MEDICAMENT66
进行中（未招募）
不适用
Phase II study evaluating oral vinorelbine as a single agent in patients with hormone receptor breast cancer with bone metastases previously treated by a hormone therapyBreast cancer with bone metastases previously treated by a hormone therapy.MedDRA version: 13.1Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-014497-18-ATPIERRE FABRE MEDICAMENT66
进行中（未招募）
不适用
Phase II study evaluating oral vinorelbine as a single agent in patients with hormone receptor positive breast cancer with bone metastases previously treated by a hormone therapy. - NDpatients with hormone receptor positive breast cancer with bone metastases previously treated by a hormone therapyMedDRA version: 12.1Level: LLTClassification code 10027475Term: Metastatic breast cancerEUCTR2009-014497-18-ITPIERRE FABRE MEDICAMENT66
进行中（未招募）
1 期
Randomised phase II trial to compare two first line chemotherapy regimen : oral vinorelbine and cisplatin followed by maintenance therapy with single agent oral vinorelbine and gemcitabine and cisplatin followed by maintenance therapy with single agent gemcitabine in Locally Advanced or Metastatic Non-Small-Cell Lung Cancer patients with squamous histological type.First line locally advanced or metastatic Non-Small-Cell Lung Cancer (NSCLC) patient with squamous histological type.MedDRA version: 14.1Level: SOCClassification code 10029104Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-003531-40-ITPIERRE FABRE MEDICAMENT110
进行中（未招募）
1 期
Study evaluating oral vinorelbine and cisplatin followed by oral vinorelbine alone versus gemcitabine and cisplatin followed by gemcitabine alone in patients with a specific type of lung cancerFirst line Locally Advanced or Metastatic Non-Small-Cell Lung Cancer patients with squamous histological typeMedDRA version: 15.1 Level: PT Classification code 10061873 Term: Non-small cell lung cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-003531-40-ATPierre Fabre Medicament113